HLS Therapeutics Inc.
HLS.TO
TSX
| 12/31/2024 | 09/30/2024 | ||||
|---|---|---|---|---|---|
| Revenue | 10.34% | -2.99% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 10.34% | -2.99% | |||
| Cost of Revenue | 14.97% | -1.32% | |||
| Gross Profit | 8.71% | -3.57% | |||
| SG&A Expenses | -9.01% | -2.43% | |||
| Depreciation & Amortization | -1.34% | -5.94% | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -0.85% | -3.42% | |||
| Operating Income | 84.15% | 6.52% | |||
| Income Before Tax | 40.08% | -205.29% | |||
| Income Tax Expenses | 244.07% | -101.45% | |||
| Earnings from Continuing Operations | 37.59% | 14.75% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 37.59% | 14.75% | |||
| EBIT | 84.15% | 6.52% | |||
| EBITDA | 40.77% | -5.64% | |||
| EPS Basic | -28.02% | 14.62% | |||
| Normalized Basic EPS | -23.44% | 1.94% | |||
| EPS Diluted | -34.45% | 15.33% | |||
| Normalized Diluted EPS | -23.44% | 1.94% | |||
| Average Basic Shares Outstanding | -4.92% | -0.12% | |||
| Average Diluted Shares Outstanding | -4.92% | -0.12% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||